Completed PHASE1 INTERVENTIONAL 2-arm NCT00287352

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

Double Blind Placebo Controlled Investigation of Amantadine for Retarding Weight Gain in First Episode Adlt Psychotic Subjects Beginning Therapy With Olanzapine.

Sponsor: Eli Lilly and Company

Conditions Mood Disorders With Psychotic Features Psychotic Disorder Schizoaffective Disorder Schizophrenia Schizophreniform Disorder

Interventions Olanzapine and placebo Olanzapine, Amantadine

Updated 6 times since 2017 Last updated: Apr 29, 2011 Started: May 31, 2005 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Mood Disorders With Psychotic Features and Psychotic Disorder and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
University of North Carolina, Chapel Hill

Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chapel Hill, United States